WO2006054494A1 - ベンゾ[c]フェナンスリジン誘導体の製造法 - Google Patents
ベンゾ[c]フェナンスリジン誘導体の製造法 Download PDFInfo
- Publication number
- WO2006054494A1 WO2006054494A1 PCT/JP2005/020733 JP2005020733W WO2006054494A1 WO 2006054494 A1 WO2006054494 A1 WO 2006054494A1 JP 2005020733 W JP2005020733 W JP 2005020733W WO 2006054494 A1 WO2006054494 A1 WO 2006054494A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- benzo
- group
- phenanthridine
- compound represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a benzo [c] phenanthridine derivative, which is an intermediate of a benzo [c] phenanthridine-um derivative that has antitumor activity and platelet aggregation inhibitory activity and is expected as a pharmaceutical product. It relates to a new manufacturing method.
- Thrombosis is caused by platelet adhesion and aggregation, and is known to be involved in cancer metastasis as well as cerebral infarction, cardiovascular disorder, cancerous DIC, and the like.
- Patent Documents 1 and 2 describe that a benzo [c] phenanthridine-um derivative having a lower alkyl substituent at the 5-position has antitumor activity and platelet aggregation inhibitory activity.
- Patent Document 3 describes that a benzo [c] phenanthridinium derivative having a structure in which a nitrogen atom at position 5 and a carbon atom at position 6 are connected by an aliphatic hydrocarbon chain has antitumor activity.
- RU 1 and 2 describe that a benzo [c] phenanthridine-um derivative having a lower alkyl substituent at the 5-position has antitumor activity and platelet aggregation inhibitory activity.
- Patent Document 3 describes that a benzo [c] phenanthridinium derivative having a structure in which a nitrogen atom at position 5 and a carbon atom at position 6 are connected by an aliphatic hydrocarbon chain has antitumor activity.
- benzo [c] phenanthridine-um derivatives described in Patent Documents 1 and 2 are intermediate to benzo [c] phenanthridine derivatives represented by the following general formula (2) or general formula (4).
- Patent Documents 1 and 2 report that this intermediate is obtained by a ring-closing reaction with an organotin hydride or an aroma reaction with an oxidizing agent.
- the benzo [c] phenanthridine-um derivative described in Patent Document 3 is synthesized using a benzo [c] phenanthridine derivative represented by the following general formula (8) as an intermediate.
- this intermediate is converted from 7-benzyloxy-8-methoxybenzo [c] phenanthridine derivative by methylation, introduction of lower alcohol, reaction with organometallic compound, and aromatization reaction using oxidant. It has been reported that it can be obtained.
- the vector represented by the general formula (2) or the general formula (4) described in Patent Documents 1 and 2 is used.
- the method for producing the nzo [c] phenanthridine derivative uses an organotin hydride.
- the method for producing a benzo [c] phenanthridine derivative represented by the general formula (8) described in Patent Document 3 is a methylated, lower-peptidic acid derivative from a 7-benzyloxy-8-methoxybenzo [c] phenanthridine derivative.
- Many processes such as introduction of alcohol, reaction with organometallic compounds, and aromatization reaction using an oxidizing agent are required.
- Patent Document 1 Japanese Patent Application Laid-Open No. 5-208959
- Patent Document 2 JP-A-7-258218
- Patent Document 3 Pamphlet of International Publication No.98Z23614
- an object of the present invention is to provide a method for producing a benzo [c] phenanthridine derivative represented by the general formula (2) or the general formula (4) without using a stannane reagent.
- Another object of the present invention is to provide a simple process for producing a benzo [c] phenanthridine derivative represented by the general formula (8) in a short process.
- the present inventor is represented by the general formula (2) or the general formula (4), which is an intermediate of the antitumor agent benzo [c] phenanthridium derivative.
- an organic radical reaction proceeds rapidly with an organic silyl hydride without using a toxic stannane reagent, and an intermediate is advantageously obtained.
- benzo [c] phenanthridine derivative represented by the general formula (8), which is an intermediate, is also used.
- the present inventors completed the present invention by finding a simple new synthesis route in a short body process.
- Rl and R2 each independently represent a hydroxyl group, a hydrogen atom or a lower alkoxy group, or R1 and R2 are bonded to each other to represent a methylenedioxy group, X represents a halogen atom, and R3 represents a protecting group]
- the compound represented by the general formula (2) is subjected to a ring-closing reaction using an organic silyl hydride, followed by an aromatic reaction with an oxidizing agent in the next step (2)
- R3 represents a protecting group
- the compound represented by the general formula (4) is subjected to a ring closure reaction using an organic silyl hydride, followed by aromatization with an oxidizing agent.
- R3 represents the same meaning as described above] is a method for producing a benzo [c] phenanthridine derivative.
- tris (trimethylsilyl) silane is particularly preferred as the organic silyl hydride.
- R4 and R5 are each independently a hydroxyl group, a hydrogen atom or a lower alkoxy group, Alternatively, R4 and R5 are bonded to each other to represent a methylenedioxy group, and X represents a halogen atom.
- M represents an aliphatic hydrocarbon chain which may have a substituent
- R 6 represents a protecting group
- W represents an organic metal or inorganic metal salt.
- an organic radical reaction proceeds rapidly with a low toxicity organic silyl hydride without using a toxic stannane reagent in the production of a benzo [c] phenanthridine derivative useful as an intermediate of an antitumor agent.
- the target compound represented by the general formula (2) or the general formula (4) can be produced under conditions that are friendly to the environment with a simple apparatus.
- the number of production steps of the 6-substituted benzo [c] phenanthridine derivative represented by the general formula (8), which is also useful as an intermediate for an antitumor agent, can be shortened and efficient production can be achieved. It was possible.
- the lower alkoxy group is preferably an alkoxy group having 1 to 5 carbon atoms, specifically, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, Examples include t-butoxy and n-pentoxy. Of these, an alkoxy group having 1 to 3 carbon atoms such as methoxy, ethoxy, n-propoxy and isopropoxy is particularly preferable.
- the lower alkyl group is preferably an alkyl group having 1 to 5 carbon atoms.
- alkyl groups having 1 to 3 carbon atoms such as methyl, ethyl, n-propyl and isopropyl are particularly preferable.
- examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- the protecting group R3 is not particularly limited as long as it is a protecting group for a phenolic hydroxyl group.
- a substituted or unsubstituted acyl group having 2 to 8 carbon atoms such as acetyl, propiol, butyryl, isobutyryl, benzoyl, black benzoyl, methylbenzoyl, etc .; isopropyl, isobutyl, t-butyl, isopetyl, 2 butyr, Examples thereof include branched alkyl groups or alkylene groups having 3 to 10 carbon atoms such as 3-methyl-2-butenyl; and substituted or unsubstituted benzyl groups such as benzyl, p-chloroguchi benzyl and p trifluorobenzoyl.
- Examples of the substituent of the substituted acyl group having 2 to 8 carbon atoms and substituted benzyl group include a lower alkoxy group, a lower alkyl group, a halogen atom, and a halogen atom-substituted lower alkyl group.
- the protecting group R3 is preferably a substituted or unsubstituted benzyl group or a branched alkyl group having 3 to 10 carbon atoms (particularly a branched alkyl group having 3 to 5 carbon atoms).
- the protecting group R6 is not particularly limited as long as it is a group generally used for protecting a hydroxyl group.
- substituted methyl groups such as methoxymethyl, benzyloxymethyl, tetrahydrofuryl, t-butyl, p-methoxybenzyl and trimethyl; tri (CI—C6) alkylsilyl groups such as t-butyldimethylsilyl and trimethylsilyl;
- Examples thereof include substituted or unsubstituted acyl groups having 2 to 8 carbon atoms such as cetyl, chloroacetyl, benzoyl and isobutyryl.
- examples of the substituent of the substituted acyl group having 2 to 8 carbon atoms include a lower alkoxy group, a lower alkyl group, a halogen atom, and a halogen atom-substituted lower alkyl group.
- the protecting group R6 is preferably a tri (CI—C6) alkylsilyl group, particularly preferably a t-butyldimethylsilyl group.
- Examples of the compound represented by the general formula (1) include the following compounds.
- the compound of the present invention is not limited.
- the compound represented by the general formula (1) is preferably the compound represented by the general formula (3).
- N— (2′monobenzyloxy-6′—bromo-3 ′ —Methoxybenzyl) -6,7-methylenedioxy 1-naphthylamine is preferred.
- Examples of the compound represented by the general formula (2) include the following compounds.
- the compound of the present invention is not limited.
- the compound represented by the general formula (2) the compound represented by the general formula (4) is preferable.
- the compound represented by the general formula (4) is preferable.
- 7-benzyloxy 2,3-methylenedioxy 8-methoxy Benzo [c] phenanthridine is preferred.
- M in the general formula (6) represents an aliphatic hydrocarbon chain which may have a substituent.
- substituent of the aliphatic hydrocarbon chain include a lower alkyl group, a lower methoxy group, a halogen atom, a lower alkoxycarbonyl group, a strong rubamoyl group, and a hydroxyl group protected with a protecting group.
- protecting group for the hydroxyl group protected by the protecting group include the protecting groups for the protecting group R6 described above.
- Examples of the aliphatic hydrocarbon chain include an alkylene group having 1 to 10 carbon atoms and a alkylene group having 2 to 10 carbon atoms.
- aliphatic hydrocarbon chain of M examples include, for example, methylene, ethylene, n-propylene, isopropylene, 2-methoxyethylene, 2-acetoxyethylene, arylene, 2-butylene, 3-methyl- 2 Examples include butenylene, methoxycarbonylmethylene, isopropoxycarbonylmethylene, and rubamoylmethylene.
- a straight-chain aliphatic hydrocarbon chain having 1 to 5 carbon atoms such as methylene, ethylene and n-propylene is preferable.
- W in the general formula (6) represents an organic metal or an inorganic metal salt
- examples of the organic metal include alkyl tin.
- examples of inorganic metal salts include lithium, magnesium, aluminum, zinc, copper and halogen salts, and magnesium salts are preferred.
- examples of the organometallic compound represented by the general formula (6) include an organolithium compound, an organomagnesium compound, an organozinc compound, and an organocopper compound, and an organomagnesium compound is preferable.
- X represents a halogen atom
- R9 represents a hydrogen atom or a protecting group.
- the benzaldehyde derivative represented by the formula is heated in toluene or benzene from 80 ° C to 110 ° C for 1 hour to 3 hours, concentrated, and water by-produced by condensation of the amino group and the aldehyde group of the benzaldehyde derivative is dissolved in toluene or benzene. Effectively removed from the system by azeotropy with benzene and concentrated.
- the dehydration condensation product (Schiff base) can be obtained almost quantitatively by repeating the operation of adding toluene or benzene to the concentrated residue and heating and concentrating as necessary 2 to 4 times.
- the obtained dehydration condensation product is a compound represented by the general formula (5) when R9 is a hydrogen atom.
- R9 is a protective group
- the condensation site double bond of the dehydration condensation product is reduced with a reducing agent to obtain a compound represented by the general formula (1).
- Any reducing agent may be used as long as it can reduce the CN double bond, but it is desirable to reduce the reaction temperature from 10 ° C to 40 ° C, especially using sodium borohydride or dimethylaminoborane. Better!/,.
- the compound represented by the general formula (1) or the general formula (3) is subjected to a ring-closing reaction, that is, a condensation reaction by a halogenated hydrogen elimination reaction, preferably with an organic silyl hydride in an organic solvent.
- organic silyl hydrides include hydrocarbon silyl hydrides having 1 to 10 carbon atoms, preferably hydrocarbon silyl hydrides having 1 to 3 carbon atoms, such as tris (trimethylsilyl) silane, triethylsilyl.
- examples thereof include hydrides and dihydrocarbon silyl hydrides having 1 to 3 carbon atoms, such as diphenylsilyl hydride. Of these, tris (trimethylsilyl) silane is preferred!
- a compound represented by the general formula (1) or the general formula (3) and 1 equivalent, 6 equivalents, preferably 1.5 to 3 equivalents of an organic silyl hydride are preferably used as an organic solvent.
- a C6 to C10 hydrocarbon solvent such as toluene, xylene or benzene, and preferably a radical initiator such as 2, 2'-azobis (isobutyl)-2,2'- Add azobis (2-methylbutyoxy-tolyl), 2, 2'-azobis (2,4'-dimethyl valero-tolyl), or benzoyl peroxide to 60 ° C to 150 ° C, preferably 80 ° C
- the ring closure can be completed by heating from C to 150 ° C. for 2 minutes to 4 hours, preferably 5 minutes to 2 hours.
- the oxidative aromatization of the ring closure with an oxidizing agent is preferably carried out at a temperature in the range of 0 to 100 ° C, preferably 10 to 40 ° C, preferably without separating the reaction mixture. 1 to 120 minutes, preferably 5 to 50 minutes, to obtain the compound represented by the general formula (2) or the general formula (4).
- oxidizing agents can be used for this reaction, for example, active diacid manganese, lead tetraacetate, mercury acetate or dichlorodisianobenzoquinone (DDQ), preferably active diacid manganese. .
- the compound represented by the general formula (2) or the general formula (4), which is the target compound, is obtained from the reaction product by an isolation 'purification method used in a usual organic synthesis reaction as required.
- the compound represented by the general formula (5) is preferably dissolved or suspended in an aprotic solvent, for example, an ether solvent such as diethyl ether, diisopropyl ether, 1,2-dimethoxyethane, tetrahydrofuran, Organometallic compound represented by general formula (6) 1-10 equivalents, preferably 3-8 equivalents, 78-50.
- an ether solvent such as diethyl ether, diisopropyl ether, 1,2-dimethoxyethane, tetrahydrofuran
- Organometallic compound represented by general formula (6) 1-10 equivalents, preferably 3-8 equivalents, 78-50.
- C preferably 0-30.
- a compound represented by the general formula (7) is obtained.
- the protecting group employed when the protecting group is introduced into the phenolic hydroxyl group of the compound represented by the general formula (7) the protecting group of the protecting group R3 described above is similarly employed.
- a protecting group it can be introduced by a commonly used method.
- DMF dimethylformamide
- a base such as potassium carbonate
- benzyl halide such as benzyl bromide or benzyl chloride
- the reaction can be carried out preferably at 0 to 30 ° C.
- the ring closure reaction can be carried out using a stannane reagent or an organic silyl hydride.
- a stannane reagent is toxic, an organic silyl hydride is preferably used.
- the ring closure reaction may be performed in an organic solvent such as benzene, toluene, or xylene.
- organic silyl hydrides include hydrocarbon silyl hydrides having 1 to 10 carbon atoms, preferably hydrocarbon silyl hydrides having 1 to 3 carbon atoms, such as tris (trimethylsilyl) silane and triethyl.
- Silyl hydride or a dihydrocarbon silyl hydride having 1 to 3 carbon atoms specifically, for example, diphenylsilyl hydride.
- organic silyl hydrides tris (trimethylsilyl) silane is preferred.
- radical ring closure reaction using tris (trimethylsilyl) silane will be further described.
- One compound equivalent to a compound in which the phenolic hydroxyl group of the compound represented by the general formula (7) is protected is protected.
- radical initiators such as 2,2′-azobis (2-isobutyoxynitrile), 2,2′-azobis (2-methylbutyoxy-tolyl), 2,2′-azobis (2,4′-dioxy) Methylvalero-tolyl) or benzoyl peroxide is heated and heated at 60 to 150 ° C, preferably 80 to 150 ° C for 2 minutes to 4 hours, preferably 5 minutes to 2 hours.
- the ring-closed product may be isolated, but preferably the compound represented by the general formula (8) is obtained by aromatizing the reaction mixture without isolation with an oxidizing agent.
- Aromatization may be carried out at 0 to 150 ° C, preferably 10 to 100 ° C, for 1 to 180 minutes, preferably 5 to 150 minutes.
- the oxidizing agent is not particularly limited, and examples thereof include manganese dioxide, lead tetraacetate, mercury acetate, and dichlorodisianobenzoquinone (DDQ), and active manganese dioxide is preferable.
- the compound represented by the general formula (8) which is the target compound, can be obtained from the reaction product by isolation and purification methods used in ordinary organic synthesis reactions.
- the compound represented by the general formula (8) is a benzo [c] phenanthridinium derivative having antitumor activity by the following method according to the same method as described in Patent Document 3. It can lead to the compound of formula (12). [Chemical 11]
- the protecting group R3 of the compound represented by the general formula (8) can be deprotected by a method suitable for each protecting group.
- a method suitable for each protecting group for example, in the case of a trialkylsilyl protecting group, tetrahydrofuran In a solvent such as acetonitrile, a fluoride salt such as tetrabutylammonium fluoride, potassium fluoride or cesium fluoride is added, and the reaction is carried out at 0 to 80 ° C., preferably 0 to room temperature. In the case of other protecting groups, it can be easily deprotected by a known deprotection reaction.
- the compound represented by the general formula (11) is converted into an acid chloride such as chloride methanesulfonate or p-toluenesulfonyl chloride or an acid anhydride such as trifluoroacetic acid.
- Cyclization is carried out by reacting the product at room temperature to 110 ° C after reaction with the product under ice-cooling to room temperature. Then, without isolating and purifying the product, when the protecting group Y is, for example, a benzyl group, debenzylation is performed by treatment at room temperature to 100 ° C under acidic conditions such as concentrated hydrochloric acid. Do.
- Other protecting groups can be easily deprotected by a well-known deprotection reaction.
- the compound obtained by deprotection is dissolved in a solvent, and this is acid-treated with an acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
- the amount of acid is about 1 to 3 moles per mole of compound.
- the compound represented by the general formula (18) is methylated with a methylating agent such as methyl p-toluenesulfonate, methyl 2-trobenzenesulfonate, or methyl trifluoromethanesulfonate, and then in the presence of a base, such as ethanol.
- a methylating agent such as methyl p-toluenesulfonate, methyl 2-trobenzenesulfonate, or methyl trifluoromethanesulfonate
- a base such as ethanol.
- a compound represented by the general formula (19) is obtained by mixing with a lower alcohol (LOH).
- the compound represented by the general formula (19) is reacted with an organometallic compound such as an organomagnesium compound represented by the general formula (6) in the presence of an aprotic solvent, and the resulting compound is oxidized again by an oxidizing agent.
- an aromatization reaction a compound represented by the general formula (8) is finally obtained.
- the partial reduction step and the methylation step in the conventional production method are omitted.
- the production method of the present invention realizes the shortening of these two steps, and obtains the benzo [c] phenanthridine derivative represented by the general formula (8) very easily without impairing the reactivity 'yield.
- the benzo [c] phenanthridine derivative can be converted to a benzo [c] phenanthridine-um derivative having antitumor activity using the method described in Patent Document 3.
- N- (2,1-benzyloxy-6, -bromo-3, -methoxybenzyl) -6,7-methylenedioxy-1-naphthylamine 10 g (20.3 mmol) was dissolved in 1 L of toluene and refluxed. To this solution, 7.57 g (30.5 mmol) of tris (trimethylsilyl) silane and 5.85 g (30.5 mmol) of 2,2,1azobis (isobutyric-tolyl) were added. 1. After 5 hours, the reaction solution was cooled to room temperature, and 12 g of activated dimanganese manganese was added and mixed for 3.5 hours. Next, manganese was filtered off and concentrated under reduced pressure.
- Example 1 As is clear from Example 1, the production method of the present invention using an organosilyl hydride impairs the reactivity 'yield without using the toxic stannane reagent used in the conventional production method.
- the obtained benzo [c] phenanthridine derivative represented by the general formula (2) or the general formula (4) has an antitumor activity using the method described in Patent Documents 1 and 2, and has the anti-tumor activity. To lead derivatives.
- reaction solution was cooled to 100 ° C., and 400 mg of active dimanganese manganese salt was added and stirred for 2.5 hours. After manganese was filtered off and concentrated under reduced pressure, 300 mL of ethyl acetate and 300 mL of aqueous sodium hydrogen carbonate solution were collected from the residue, transferred to a separatory funnel, and extracted with ethyl acetate. The organic layer is dehydrated over anhydrous sodium sulfate, filtered and concentrated.
- Example 1 As apparent from Example 1, the production method of the present invention using an organosilyl hydride impairs the reactivity 'yield without using the toxic stannane reagent used in the conventional production method. Thus, a benzo [c] phenanthridine derivative can be obtained while ensuring safety such as after-treatment.
- the obtained benzo [c] phenanthridine derivative represented by the general formula (2) or the general formula (4) has an antitumor activity using the method described in Patent Documents 1 and 2, and has the anti-tumor activity. To lead derivatives.
- Example 2 As is clear from Example 2, the production method of the present invention in which the partial reduction step in the above conventional production method and the step of methyl alcohol are omitted is extremely simple without impairing both the reactivity and the yield.
- a benzo [c] phenanthridine derivative represented by the general formula (8) can be obtained.
- the benzo [c] phenanthridine derivative can be converted to a benzo [c] phenanthridine-mum derivative having antitumor activity using the method described in Patent Document 3.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05806279A EP1813617A1 (en) | 2004-11-17 | 2005-11-11 | PROCESS FOR PRODUCING BENZOÝc¨PHENANTHRIDINE DERIVATIVE |
US11/664,964 US20090048446A1 (en) | 2004-11-17 | 2005-11-11 | Process For Producing Benzo[C]Phenanthridine Derivative |
CA002584617A CA2584617A1 (en) | 2004-11-17 | 2005-11-11 | Process for producing benzo[c]phenanthridine derivative |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-333763 | 2004-11-17 | ||
JP2004-333776 | 2004-11-17 | ||
JP2004333763A JP2006143625A (ja) | 2004-11-17 | 2004-11-17 | ベンゾ[c]フェナンスリジン誘導体の製造法 |
JP2004333776A JP4518318B2 (ja) | 2004-11-17 | 2004-11-17 | ベンゾ[c]フェナンスリジン誘導体の新規製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006054494A1 true WO2006054494A1 (ja) | 2006-05-26 |
Family
ID=36407038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020733 WO2006054494A1 (ja) | 2004-11-17 | 2005-11-11 | ベンゾ[c]フェナンスリジン誘導体の製造法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090048446A1 (ja) |
EP (1) | EP1813617A1 (ja) |
KR (1) | KR20070085307A (ja) |
CA (1) | CA2584617A1 (ja) |
TW (1) | TW200626554A (ja) |
WO (1) | WO2006054494A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04173789A (ja) * | 1990-11-07 | 1992-06-22 | Nippon Kayaku Co Ltd | ベンゾ〔c〕フェナンスリジニューム誘導体の製造法 |
-
2005
- 2005-11-11 US US11/664,964 patent/US20090048446A1/en not_active Abandoned
- 2005-11-11 EP EP05806279A patent/EP1813617A1/en not_active Withdrawn
- 2005-11-11 WO PCT/JP2005/020733 patent/WO2006054494A1/ja active Application Filing
- 2005-11-11 CA CA002584617A patent/CA2584617A1/en not_active Abandoned
- 2005-11-11 KR KR1020077010734A patent/KR20070085307A/ko not_active Application Discontinuation
- 2005-11-14 TW TW094139924A patent/TW200626554A/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04173789A (ja) * | 1990-11-07 | 1992-06-22 | Nippon Kayaku Co Ltd | ベンゾ〔c〕フェナンスリジニューム誘導体の製造法 |
Non-Patent Citations (3)
Title |
---|
GIESE B. ET AL: "Tris(trimethylsilyl)silane as Mediator in Organic Synthesis via Radicals", TETRAHEDRON LETTERS, vol. 30, no. 6, 1989, pages 681 - 684, XP002995266 * |
LESAGE M. ET AL: "Tris(trimethylsilyl)silane: A Catalyst for Radical Mediated Reduction Reactions", TETRAHEDRON LETTERS, vol. 30, no. 21, 1989, pages 2733 - 2734, XP002995265 * |
NAKANISHI T. ET AL: "Synthesis of NK109, an Anticancer Benzo[c]phenanthridine Alkaloid", JOURNAL OF ORGANIC CHEMISTRY, vol. 63, no. 13, 1998, pages 4235 - 4239, XP002995264 * |
Also Published As
Publication number | Publication date |
---|---|
CA2584617A1 (en) | 2006-05-26 |
EP1813617A1 (en) | 2007-08-01 |
US20090048446A1 (en) | 2009-02-19 |
TW200626554A (en) | 2006-08-01 |
KR20070085307A (ko) | 2007-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109678796B (zh) | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 | |
US7375236B2 (en) | Methods for producing cyclic benzamidine derivatives | |
CN103694237B (zh) | 一种抗凝血药阿哌沙班的制备方法及关键中间体 | |
Iwao et al. | New synthetic approach to pyrroloiminoquinone marine alkaloids. Total synthesis of makaluvamines A, D, I, and K | |
CN103113293B (zh) | 多取代喹啉衍生物及其制备方法 | |
JP6332818B2 (ja) | チカグレロルの中間体およびその製造法、およびチカグレロルの製造法 | |
JP5762624B2 (ja) | 安定な7員環ラクトンを含むカンプトテシン化合物、それらの製造方法及び使用 | |
WO2016031796A1 (ja) | ホモジナイザーを用いる抗腫瘍剤の製造方法 | |
Anderson et al. | Synthesis and murine antineoplastic activity of bis [carbamoyloxymethyl] derivatives of pyrrolo [2, 1-a] isoquinoline | |
Cho et al. | Synthesis and antiproliferative activity of new aminoisoquinolinylurea derivatives against melanoma cell line | |
CN101754951A (zh) | 用于制备fmoc基可水解连接体的方法 | |
WO2006054494A1 (ja) | ベンゾ[c]フェナンスリジン誘導体の製造法 | |
JPS6247193B2 (ja) | ||
WO2004022514A1 (ja) | スピロフルオレノールの製造方法 | |
KR101648595B1 (ko) | 치환된 이소퀴놀린의 합성 방법 | |
CN115819391A (zh) | 一类黄芩素衍生物、其制备方法和用途 | |
JP4038245B2 (ja) | 新規なフェナンスリジニウム誘導体 | |
JP5265144B2 (ja) | 3−o−置換−カテキン類誘導体の新規製造方法 | |
JP2006143625A (ja) | ベンゾ[c]フェナンスリジン誘導体の製造法 | |
JP4518318B2 (ja) | ベンゾ[c]フェナンスリジン誘導体の新規製造法 | |
CN1587265A (zh) | 10-烷氧基喜树碱衍生物及其制备方法与应用 | |
CN1162404C (zh) | 合成用于制备三环化合物的中间体的方法 | |
KR100396431B1 (ko) | 2-술포닐피리딘 유도체 및 2-[((2-피리딜)메틸)티오]-1h-벤즈이 | |
WO2022111449A1 (zh) | 一种btk降解剂的制备方法 | |
CN115611894A (zh) | 一种含氮螺环化合物或其药学上可接受的盐及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11664964 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005806279 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2584617 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077010734 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580039357.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005806279 Country of ref document: EP |